Sacubitril-Valsartan in Patients Requiring Hemodialysis
In this comparative effectiveness study of patients with HFrEF requiring hemodialysis, sacubitril-valsartan therapy was associated with beneficial effects in all-cause mortality and all-cause hospitalization.
Authors
- Morgan E. Grams (ORCID: https://orcid.org/0000-0002-4430-6023)
- Jung‐Im Shin (ORCID: https://orcid.org/0000-0003-0374-6927)
- Josef Coresh (ORCID: https://orcid.org/0000-0002-4598-0669)
- Dustin Le (ORCID: https://orcid.org/0000-0003-3231-6758)
Institutions
- Johns Hopkins University (US)
- New York University (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2024-08-20
- DOI
- https://doi.org/10.1001/jamanetworkopen.2024.29237
- Citations
- 16
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 6.43
Funders
- National Heart, Lung, and Blood Institute
- National Institute of Diabetes and Digestive and Kidney Diseases